Moody's Says Alkermes (ALKS) FORWARD-5 Data is Credit-Positive Development
Tweet
Share
E-mail
Get Alerts ALKS Hot Sheet
Join SI Premium – FREE
Moody's Investors Service commented that the positive clinical data of Alkermes' (Nasdaq: ALKS) experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Weakness in this biotech stock is a buying opportunity: Mizuho
- Tempus AI Inc (TEM) PT Lowered to $70 at BTIG
- Alkermes (ALKS) PT Raised to $58 at Baird
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors ServiceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
